The Nausea Care App in patients receiving chemotherapy: A Randomized Controlled Trial

Withdrawn

• Conditions: Patienten die chemotherapie krijgen voor mamma-, ovarium-, hodgkin-, non-hodgkin; Nausea; vomiting

• Registration Number: NL-OMON43482
• Lead Sponsor: Oncologie

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 23 April 2024

Recruitment & Eligibility

• Status: Withdrawn
• Sex: Not specified
• Target Recruitment: 206

Inclusion Criteria

- Adulta (18+)
- Diagnosed with oncologic disease
- Precription with AC, TAC, R-CHOP, ABVD, Taxol/Carboplatin
- Able to read and speake Dutch
- Own a smartphone (Iphone, Android)
- Capable to give written informed consent

Exclusion Criteria

- Patient who received chemotherapy prior to study participation

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>The main study parameter include differences between NCAG and CG, regarding:<br /><br>Chemotherapy induced nausea measured as a patient reported visual analoge scale<br /><br>(VAS) and defined as a VAS equal or above 5 mm.</p><br>

Secondary Outcome Measures

Name	Time	Method
<p>- Number of days including occurence of nausea.<br /><br>- Number of days including occurrence of vomiting<br /><br>- Number of days including usage of escape medication<br /><br>- QoL-scores<br /><br><br /><br>Numbers and percentages of NCAG who:<br /><br>- find the NCA easy to download<br /><br>- find the instructions clearly described<br /><br>- received information as requested<br /><br>- find the NCA useful as a reminder for taking anti-emetics<br /><br>- would recommend the NCA to other patients<br /><br><br /><br>Contacting the ward by NCAG and CG:<br /><br>- number of days including extra visits<br /><br>- number of days including extra phone calls</p><br>